New pediatric data shoot Rocket's gene therapy toward phase 2, leaving behind FDA concerns

Having overcome FDA trial issues last year, Rocket Pharmaceuticals expects the latest early-stage data for its heart disease drug to give the gene therapy a long-awaited boost into phase 2 trials.